Juniper Pharma (Formerly known as Columbia Laboratories)
4 Liberty Square
274 articles about Juniper Pharma (Formerly known as Columbia Laboratories)
BioSpace Movers and Shakers Nov. 5
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals, Inc.
Catalent, Inc. announced the successful completion of the previously announced tender offer by Catalent Boston, Inc.
Juniper Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results
Signs Agreement to be Acquired by Catalent, Inc.
CORRECTING and REPLACING Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.
$133 Million Deal Adds European Early Development Center of Excellence to Global Network CORRECTION...by Catalent, Inc.
Shares of Juniper Pharmaceuticals have soared more than 31 percent in premarket trading after the company announced it will be acquired by drug delivery company Catalent, Inc. in a deal with a total equity value of approximately $139.6 million.
Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.
$133 Million Deal Adds European Early Development Center of Excellence to Global Network.
Juniper Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results
Core Businesses Driving Strong Financial Performance CRINONE® Revenues Increased 30% and Juniper Pharma Services (JPS) Revenues Increased 55% Year-over-Year Conference Call at 8:30 a.m. EDT Today
Juniper Pharmaceuticals to Report First Quarter 2018 Results on May 10, 2018
Juniper Pharmaceuticals will hold a conference call on May 10, 2018, to discuss the financial results for the first quarter ended March 31, 2018.
Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience
Juniper Pharmaceuticals, Inc. announced an exclusive worldwide license agreement with Daré Bioscience for the development and commercialization of the Company's intravaginal ring (IVR) technology platform.
Juniper Pharmaceuticals Appoints Richard Messina to Board of Directors
Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service pharmaceutical development and manufacturing business JPS, today announced the appointment of Richard Messina to the Company's Board of Directors.
Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results
Full Year CRINONE® Revenues Increased 20% and Juniper Pharma Services (JPS) Revenues Increased 32% Year-over-Year Ended 2017 Cash Flow Positive; Company Expects Trend to Continue in 2018 Conference Call at 8:30 a.m. EST Today
Juniper Pharmaceuticals to Explore Strategic Alternatives
The Company has engaged Rothschild as its independent financial advisor to assist Juniper and its Board of Directors in evaluating potential strategic alternatives.
Juniper Pharma Announces 4.5-Year Extension Through 2024 of CRINONE® Supply Agreement with Merck KGaA, Darmstadt, Germany
Juniper Pharma today announced the extension of its supply agreement for CRINONE with an affiliate of Merck KGaA, Darmstadt, Germany.
Juniper Pharma Outlines Strategic Priorities for 2018 and Reports Recent Portfolio Progress
Juniper Pharma today provided financial guidance for 2018, reflecting continued strength in the Company's core businesses, JPS and CRINONE, and provided an overview of strategic priorities for 2018.
Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results
Cash and cash equivalents were $22.1M at September 30, 2017, an increase of 3% from June 30, 2017.
Juniper Pharmaceuticals to Report Third Quarter 2017 Results on November 2, 2017
Juniper Pharma, will hold a conference call on November 2, 2017, to discuss the financial results for the third quarter ended September 30, 2017.
Juniper Pharma Appoints Jennifer Good To Board Of Directors
Juniper Pharma Reports Second Quarter 2017 Financial And Operating Results
Juniper Pharma To Report Second Quarter 2017 Results On August 3, 2017
Juniper Pharma Announces Results Of 2017 Annual Meeting